Michael Okunewitch
Stock Analyst at Maxim Group
(0.55)
# 4,096
Out of 5,182 analysts
26
Total ratings
24%
Success rate
-17.72%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.16 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $0.78 | +1,186.01% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $0.68 | +782.61% | 3 | Sep 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $0.35 | +9,837.54% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.49 | +167.26% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.70 | +1,547.06% | 2 | Feb 20, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.51 | +98.68% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.79 | +123.46% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $240 | $1.37 | +17,418.25% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.12 | +435.71% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.98 | +1,124.49% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.61 | +1,390.68% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.44 | +637.70% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $0.90 | +225,150.28% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.65 | +41.64% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.26 | +2,235.54% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.79 | +559.63% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.82 | +12,169.94% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.16
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $0.78
Upside: +1,186.01%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $0.68
Upside: +782.61%
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $0.35
Upside: +9,837.54%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.49
Upside: +167.26%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.70
Upside: +1,547.06%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.51
Upside: +98.68%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.79
Upside: +123.46%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $240
Current: $1.37
Upside: +17,418.25%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.12
Upside: +435.71%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.98
Upside: +1,124.49%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.61
Upside: +1,390.68%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.44
Upside: +637.70%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $0.90
Upside: +225,150.28%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.65
Upside: +41.64%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $0.26
Upside: +2,235.54%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.79
Upside: +559.63%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.82
Upside: +12,169.94%